Celator Pharmaceuticals Inc


Stock Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces VYXEOS™ (CPX-351) Shows No QT/QTc Interval Prolongation

Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that a Phase 2 pharmacokinetic and pharmacodynamics (PK/PD) study evaluating the effects of VYXEOS™ (CPX-351) on cardiac depolarization/repolarization has …

Company Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces Positive Recommendation From Data And Safety Monitoring Board For Phase 3 Study Of CPX-351

Celator Pharmaceuticals Inc (NASDAQ:CPXX) announced that the independent Data and Safety Monitoring Board (DSMB) for the Company’s Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) …

Company Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces Positive Results from R&D Programs

Celator Pharmaceuticals Inc (NASDAQ:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, …

Stock Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces 2Q:15 Financial Results and Business Update

Celator Pharmaceuticals Inc (NASDAQ:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, …

Roth Capital Reiterates Buy on Celator Pharmaceuticals Inc Following Analyst and Investor Day

In a research report published Friday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celator Pharmaceuticals Inc (NASDAQ:CPXX) with a price target …

Roth Capital Weighs in on Celator Pharmaceuticals Inc (CPXX) Following Completion of Enrollment in Phase II Study of CPX-351

Roth Capital’s healthcare analyst Joseph Pantginis came out with a few insights on Celator Pharmaceuticals Inc (NASDAQ:CPXX), after the company announced enrollment completion of the supporting PK/PD …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts